Advisory Research’s Relmada Therapeutics RLMD Stock Holding History

Advisory Research’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9,647	Closed	-$357K	–	398
2022 Q3	$357K	Buy	+9,647	New	+$267K	0.03%	269

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advisory Research's RLMD Position: Q4 2022 in Review

Advisory Research sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 9,647 shares — an estimated $357K sold.

Advisory Research first reported a position in RLMD in Q3 2022 and held it in 1 quarter. The position peaked at $357K in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

Advisory Research reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
Advisory Research sold 9,647 Relmada Therapeutics shares in Q4 2022, an estimated $357K.
Advisory Research first reported a position in Relmada Therapeutics in Q3 2022 and held it in 1 quarter.
Advisory Research's Relmada Therapeutics position peaked at $357K in Q3 2022.
110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Advisory Research's 13F filing for Q4 2022, filed 13 Feb 2023.